CVS Health raised its full-year 2026 profit guidance to $7.90 to $8.10 per share, with the upper end of the range at $8.10, after the pharmacy and health insurance company reported a second-quarter earnings beat on August 5, 2026. The company’s adjusted earnings per share for Q2 reached $2.58, reflecting strong performance across its businesses.
The company’s second-quarter total revenues increased to $106.1 billion, up 7.3% year-over-year. Adjusted operating income surged 35.4% compared to the prior year, driven by increases across all operating segments, according to the official earnings release.
CVS’s turnaround in its health insurance business was a key driver of the results. The Health Care Benefits segment, which includes the company’s Aetna insurance operations, saw adjusted operating income jump 85.5% year-over-year. This improvement reflected better underlying performance in the Government business and the absence of a $471 million premium deficiency reserve that had weighed on results in the prior year.
The medical benefit ratio—a key metric for insurance profitability—improved to 87.4% in Q2 from 89.9% in the prior year. A lower ratio indicates better profitability, as it measures how much of premium revenue goes toward paying health care claims. The company attributed the improvement to stronger Government business performance and the absence of the prior-year reserve.
Broader Performance Across All Segments
Beyond insurance, CVS’s pharmacy benefit management and retail pharmacy operations also contributed to the strong quarter. The Health Services segment, which includes pharmacy benefit management, saw adjusted operating income increase 10.0%, while the Pharmacy & Consumer Wellness segment posted a 10.2% increase in adjusted operating income.
The company generated year-to-date cash flow from operations of $10.6 billion and raised its full-year cash flow guidance to at least $11.5 billion from the prior guidance of at least $9.5 billion.
CVS also announced operational updates reflecting its expansion into weight management treatments. The company launched comprehensive GLP-1 support across its CVS Pharmacy and MinuteClinic locations, including a $29 MinuteClinic virtual visit for eligible adults to access GLP-1 therapy evaluation and prescription services. CVS Pharmacy also participates in the Centers for Medicare & Medicaid Services Medicare GLP-1 Bridge program, which runs through December 31, 2027, offering eligible Medicare beneficiaries certain GLP-1 medications for $50 per month.
In a statement, CVS Health Chairman and CEO David Joyner said the company’s integrated model continues to deliver strong performance by enabling customers to access simple, connected and convenient health care. The company noted it is maintaining a cautious view for the remainder of 2026 in light of continued elevated cost trends and the potential for macro headwinds, even as it raised guidance based on first-half results.
Sources
- CVS Health Investor Relations — Official Q2 2026 earnings release with adjusted EPS of $2.58, full-year guidance raised to $7.90-$8.10, and segment performance details
- Barron’s — Wall Street analyst consensus expectations for Q2 2026 results
